Advertisement

Facteurs pronostiques des tumeurs épithéliales malignes de l’ovaire

  • R. Largillier
  • W. Lescaut
  • J.-M. Ferrero
  • J.-P. Guastalla
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Link CJ Jr, Reed E, Sarosy G, Kohn EC (1996) Borderline ovarian tumors. Am J Med 101(2): 217–25PubMedGoogle Scholar
  2. 2.
    Bell DA. Ovarian surface epithelial-stromal tumors. Hum Pathol. 1991; 22(8): 750–62CrossRefPubMedGoogle Scholar
  3. 3.
    Cancer Research UK, Cancer Stats Ovarian Cancer-UK (2004)Google Scholar
  4. 4.
    Jemal A, Murray T, Samuels A et al. (2003) Cancer statistics. CA Cancer J lin 53(1): 5–26Google Scholar
  5. 5.
    Harries M, Gore M (2002) Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 3(9): 529–36PubMedGoogle Scholar
  6. 6.
    Gasparini G, Pozza F, Harris AL (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 4; 85(15): 1206–19. (Erratum in: J Natl Cancer Inst 85(19): 1605)Google Scholar
  7. 7.
    Laupacis A, Wells G, Richardson WS, Tugwell P (1994) Users’ guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group JAMA 20; 272(3): 234–7Google Scholar
  8. 8.
    Trimbos JB, Parmar M, Vergote I et al. (2003) International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 15; 95(2): 105–12Google Scholar
  9. 9.
    Standards, Options et Recommandations (1998) Tumeurs épithéliales malignes de l’ovaire. Fédération nationale des centres de lutte contre le cancer. Ed John Libbey-EurotextGoogle Scholar
  10. 10.
    Agarwal R, Kaye SB (2005) Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol 16(1): 4–6CrossRefPubMedGoogle Scholar
  11. 11.
    TNM Classification des tumeurs malignes — Union internationale contre le cancer — 6e édition. 2003, Cassini. ISBN 2-84225-071-0Google Scholar
  12. 12.
    Heintz AP, Odicino F, Maisonneuve P et al. (2001) Carcinoma of the Fallopian tube. J Epidemiol Biostat 6(1): 89–103PubMedGoogle Scholar
  13. 13.
    Potter ME, Hatch KD, Soong SJ et al. (1992) Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol 44(1): 3–9CrossRefPubMedGoogle Scholar
  14. 14.
    Stockle E, Bussieres E, Stockle M et al. (1993) Is there a place for 2nd look laparotomy in the treatment of ovarian cancers? Bull Cancer 80(7): 629–38PubMedGoogle Scholar
  15. 15.
    Reuter KL, Griffin T, Hunter RE (1989) Comparison of abdominopelvic computed tomography results and findings at second-look laparotomy in ovarian carcinoma patients. Cancer 15; 63(6): 1123–8Google Scholar
  16. 16.
    Luesley D, Lawton F, Blackledge G et al. (1988) Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 10; 2(8611): 599–603Google Scholar
  17. 17.
    Miller DS, Spirtos NM, Ballon SC et al. (1992) Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer. Cancer 15; 69(2): 502–10Google Scholar
  18. 18.
    Lund B, Williamson P, van Houwelingen HC, Neijt JP (1990) Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res 1; 50(15): 4626–9Google Scholar
  19. 19.
    Pfleiderer A (1995) Ovarian Cancer. In: Hermanek P, Gospodarowicz MK, Henson DE et al. (eds) Prognostic facotrs in cancer. Berlin, Heidelberg, New York: Springer: 263–70Google Scholar
  20. 20.
    Meyer T, Rustin GJ (2000) Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82(9): 1535–8PubMedGoogle Scholar
  21. 21.
    Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, GINECO Group et al. (2004) HER-2 overexpresson is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO Group. Ann Oncol 15(1): 104–12CrossRefPubMedGoogle Scholar
  22. 22.
    Riener EK, Arnold N, Kommoss F et al. (2004) The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecol Oncol 95(1): 89–94CrossRefPubMedGoogle Scholar
  23. 23.
    Hogdall EV, Christensen L, Kjaer SK et al. (2003) Distribution of HER-2 overexpression in ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98(1): 66–73PubMedGoogle Scholar
  24. 24.
    Lassus H, Leminen A, Vayrynen A et al. (2004) ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 92(1): 31–9CrossRefPubMedGoogle Scholar
  25. 25.
    Bookman MA, Darcy KM, Clarke-Pearson D et al. (2003) Evaluation of monoclonal humanized anti-HER2 anti-body, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21(2): 283–90CrossRefPubMedGoogle Scholar
  26. 26.
    Nielsen JS, Jakobsen E, Holund B et al. (2004) Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 14(6): 1086–96CrossRefPubMedGoogle Scholar
  27. 27.
    Skirnisdottir I, Seidal T, Sorbe B (2004) A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer 14(2): 259–70CrossRefPubMedGoogle Scholar
  28. 28.
    Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broet P, Marmey B, Chauvenet L, Audouin J, Pujade-Lauraine E, Camilleri-Broet S (2004) GINECO Group. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer 2; 91(3): 470–5Google Scholar
  29. 29.
    Herbst RS (2003) Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 30(3 Suppl 7): 34–46PubMedGoogle Scholar
  30. 30.
    Lee P, Rosen DG, Zhu C et al. (2005) Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 96(3): 671–7CrossRefPubMedGoogle Scholar
  31. 31.
    Hempling RE, Piver MS, Eltabbakh GH, Recio FO (1998) Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am J Clin Oncol 21(5): 447–51CrossRefPubMedGoogle Scholar
  32. 32.
    Havrilesky L, Darcy M, Hamdan H et al. (2003) Gynecologic Oncology Group Study. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 15; 21(20): 3814–25Google Scholar
  33. 33.
    Wang Y, Helland A, Holm R et al. (2004) TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer 9; 90(3): 678–85Google Scholar
  34. 34.
    Spentzos D, Levine DA, Ramoni MF et al. (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 1; 22(23): 4700–10Google Scholar
  35. 35.
    Alberts DS, Dahlberg S, Green SJ et al. (1993) Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer 15; 71(2 Suppl): 618–27Google Scholar
  36. 36.
    Thigpen T, Brady MF, Omura GA et al. (1993) Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 15; 71(2 Suppl): 606–14Google Scholar
  37. 37.
    Massi D, Susini T, Savino L et al. (1996) Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. Cancer 15; 77(6): 1131–6Google Scholar
  38. 38.
    Partridge EE, Gunter BC, Gelder MS et al. (1993) The validity and significance of substages of advanced ovarian cancer. Gynecol Oncol 48(2): 236–41CrossRefPubMedGoogle Scholar
  39. 39.
    Petignat P, Fioretta G, Verkooijen HM et al. (2004) Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol 13(4): 181–6CrossRefPubMedGoogle Scholar
  40. 40.
    Lund B, Williamson P (1991) Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol 2(4): 281–7PubMedGoogle Scholar
  41. 41.
    Griffith CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. J Natl Cancer Instit Monogr 42: 101–4Google Scholar
  42. 42.
    Levin L, Lund B, Heintz AP (1993) Advanced ovarian cancer. An overview of multi-variate analyses of prognostic variables with special reference to the role of cytoreductive surgery. Ann Oncol 4Suppl 4: 23–9PubMedGoogle Scholar
  43. 43.
    Hacker NF, Berek JS, Lagasse LD et al. (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413–20PubMedGoogle Scholar
  44. 44.
    Hoskins WJ (1994) Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 55(3pt2): S91–6PubMedGoogle Scholar
  45. 45.
    Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 1; 20(5): 1248–59Google Scholar
  46. 46.
    Eisenkop SM, Spirtos NM, Friedman RL et al. (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90(2): 390–6CrossRefPubMedGoogle Scholar
  47. 47.
    Van der Burg ME, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 9; 332(10): 629–34Google Scholar
  48. 48.
    Rose PG, Nerenstone S, Brady MF et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 9; 351(24): 2489–97Google Scholar
  49. 49.
    Gadducci A, Sartori E, Maggino T et al. (1998) Analysis of failures after negative secondlook in patients with with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol 68: 150–5CrossRefPubMedGoogle Scholar
  50. 50.
    Voest EE, van Houwelingen JC, Neijt JP (1989) A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk) as main objectives. Eur J Cancer Clin Oncol 25(4): 711–20CrossRefPubMedGoogle Scholar
  51. 51.
    Hunter RW, Alexander ND, Soutter WP (1992) Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166(2): 504–11PubMedGoogle Scholar
  52. 52.
    Crawford SM, Peace J (2005) Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 16(1): 47–50CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • R. Largillier
  • W. Lescaut
  • J.-M. Ferrero
  • J.-P. Guastalla

There are no affiliations available

Personalised recommendations